Correction to: Nature Reviews Immunology https://doi.org/10.1038/s41577-023-00877-7, published online 15 May 2023.
In the version of the article initially published, there was an error in Fig. 2 where pembrolizumab was included but has been removed as it is not a protein kinase inhibitor. In Table 3, a dividing line between Povorcitinib and Tofacitinib was missing and has now been added. These corrections have been made to the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Castelo-Soccio, L., Kim, H., Gadina, M. et al. Author Correction: Protein kinases: drug targets for immunological disorders. Nat Rev Immunol 24, 79 (2024). https://doi.org/10.1038/s41577-023-00976-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-023-00976-5
